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There is an urgent need to develop methods that lower costs of using 
recombinant human bone morphogenetic proteins (BMPs) to promote bone 
induction. In this study, we demonstrate the osteogenic effect of a low molecular 
weight compound, SVAK-12, that potentiated the effects of BMP-2 in inducing 
transdifferentiation of C2C12 myoblasts into the osteoblastic phenotype.  
Here we report a specific compound, SVAK-12, which was selected based 
on in silico screenings of small molecule databases using the homology modeled 
interaction-motif of Smurf1-WW2 domain. The enhancement of BMP-2 activity by 
SVAK-12 was characterized by evaluating a BMP-specific reporter activity and by 
monitoring the BMP-2-induced expression of mRNA for osteocalcin and alkaline 
phosphatase which are widely accepted marker genes of osteoblast differentiation. 
Finally, we confirmed these results by also measuring the enhancement of 
BMP-2-induced activity of alkaline phosphatase.  
Smurf1 is an E3 ligase that targets osteogenic Smads for ubiquitin 
mediated proteasomal degradation. Smurf1 is an interesting potential target to 
enhance bone formation based on the positive effects on bone of proteins that block 



































































Smurf1 via its WW2 domain, we performed in silico screening to identify 
compounds that might interact with the Smurf1 Ww2 domain. We recently reported 
the activity of a compound, SVAK-3. However, SVAK-3, while exhibiting 
BMP-potentiating activity, was not stable and thus warranted a new search for a 
more stable and efficacious compound among a selected group of candidates. In 
addition to being more stable, SVAK-12 exhibited a dose-dependent activity in 
inducing osteoblastic differentiation of myoblastic C2C12 cells even when multiple 
markers of the osteoblastic phenotype were parallelly monitored.   
Key Words: BMP-2, Smad, Smurf1, Virtual Screening, potentiating 
Abbreviations: bone morphogenetic protein, BMP; Smad Ubiquitin Regulatory 
Factor-1, Smurf1; Reverse transcriptase- polymerase chain reaction, RT-PCR; 
alkaline phosphatase, ALP; dimethylsulfoxide, DMSO; Relative Units of Luciferase, 





































































The process of cell differentiation is regulated by several cytokines. 
Among the osteogenic proteins that have been reported, the Bone Morphogenetic 
Protein (BMP) family members are the most notable cytokines for their unique 
ability to promote differentiation of mesenchymal stem cells and pre-osteoblastic 
cells into osteoblasts in vitro and also to induce ectopic bone formation in vivo [1]. 
Recombinant human BMP-2 was approved by the FDA in 2002 and is being used 
clinically as a bone graft substitute to achieve spinal fusion and fracture repair. 
However the requirement for a 15,000-fold higher concentration in humans (1.5 
mg/ml) than in cell culture (100 ng/ml) creates a huge translational barrier for 
routine clinical use due to high cost [2-6]. In this study, we describe a compound 
that exhibits a strong potentiating activity on BMP-2. 
Smurf1 disruption is a potential therapeutic strategy to increase BMP 
responsiveness. Interest in Smurf1 as a target is supported by the observation that 
Smurf1-/- mice exhibit an age-dependent increase in bone mass [7]. Smurf1 
transgenic mice showed decreased bone volume and a reduced bone formation 
rate [8]. LIM Mineralization Protein-1 (LMP-1) can enhance BMP-2 activity by 
increasing cellular responsiveness to BMP-2 [9, 10]. LMP-1 exerts at least a part of 



































































degradation of Smads 1, 5 and 8 [9].  We modeled the binding domains of Smurf1 
and its Smad target peptides in a recent report [11, 12]. Our overall goal is to 
translate our knowledge of the modeled Smurf1-WW2 domain structure into 
therapeutic applications for clinical bone-induction.  Unlike recombinantly prepared 
proteins or synthetic peptides, the use of drug-like, low molecular weight 
compounds has several advantages, including blocking all the activity mediated by 
the Smurf1 WW2 domain, better cell permeability, and better in vivo stability and 
bioavailability. In this report, compounds that were selected by virtual screening, are 
evaluated for their osteogenic activity for their potential use as drugs that promote 
BMP-2 activity.  
In this study, we focus on identifying a low molecular weight compound as 
a reagent that potentiates BMP-2 activity from a set of lead compounds that were 
previously selected based on computational homology modeling [11], docking, and 
in silico screening of commercially available small molecular compounds. The 
selected compounds were predicted to possess features similar to the PPXY motif 
of Smads that interact with Smurf1, as determined by Ludi docking scores. The 
BMP-potentiating activities of the compounds were evaluated by monitoring several 
markers of the osteoblastic phenotype corresponding to various time points during 



































































osteoblasts. We used this phenotypically stable cultured cell line as an in vitro 
model system to study inducible effects in which the direct change is differentiation. 
The extremely low cost of SVAK-12 and its high stability and availability make it 
appealing for use in bone regenerative medicine. Our findings serve as a basis to 



































































MATERIALS AND METHODS 
Cell culture 
Mouse C2C12 cells and Dulbecco‟s modified Eagle‟s medium (DMEM) 
were purchased from ATCC (Manassas, VA). The non-heat inactivated fetal bovine 
serum (FBS) was purchased from HyClone Laboratories, Inc. (Logan, UT). The 
C2C12 cells at passages 5 to 10 were subcultured in T-75 cm2 flasks in DMEM 
supplemented with 10 % FBS at 37°C in 5 % CO2 with humidification. When the 
flasks reached 80 % confluence, the cells were trypsinized and seeded in triplicate 
at 200,000 cells/well in a 6-well plate for quantitative real-time RT-PCR and alkaline 
phosphatase (ALP) assays or at 50,000 cells/well in a 12-well plate for the 
dual-luciferase reporter assay. 
In silico screening of small molecular databases 
 We used the chemical database (Chemicals Available for Purchase- CAP) 
(Accelrys Inc.) for compound screenings. We accessed 70,000 molecules in the 
database supplied by Accelrys Inc. The WW2-domain structure of Smurf1 served as 
a model for receptor-based in silico screenings. The screening was performed using 
the program LUDI, de novo receptor docking procedure. LUDI, which can be 



































































method for the de novo design and positioning of ligands for proteins [13, 14]. The 
LUDI score is a sum of five contributions: ideal hydrogen bonds, perturbed ionic 
interactions (interaction of donor/acceptor in the receptor, e.g. COO-, or NH3+), 
lipophilic interactions, the freezing of internal degrees of freedom of the ligand, and 
the loss of translational and rotational entropy of the ligand. In receptor mode, LUDI 
searches a fragment library for complementary small molecules that best bind the 
defined interaction sites. During the “search and fit” the LUDI program also 
determines the energy estimates, or scores, for each conformation of the selected 
fragments in the library.  
Each molecule in our databases with a molecular weight between 200 and 
700 was docked into the targeted binding site in the WW2 domain of Smurf1. Based 
on the binding models of these compounds predicted by LUDI, the top 10% of the 
high scoring compounds from the CAP database were extracted. This output was 
further refined by excluding redundant analogs of the same scaffold. Of the 
best-scored 300 compounds selected, samples of 54 compounds were obtained 
from different vendors.  



































































The C2C12 cells were plated at a density of 200,000 cells/well in 6-well 
plates and grown overnight in DMEM containing 10% FBS. On day 2, the culture 
medium was replaced with DMEM containing 2 % FBS and the cells were treated 
with various concentrations of selected compound (diluted from 10 mg/ml stock 
solutions prepared in DMSO) for 24 hours.  In control cultures, a DMSO solvent 
concentration of 0.01% (v/v) was applied. On day 3, medium was replaced with 
fresh DMEM containing 2% FBS and the cells were treated with BMP-2 for 24 
hours.  
Total RNA was harvested using the RNeasy Mini Kit according to the 
manufacturer‟s instructions (Qiagen, Valencia, CA). The harvested RNA was 
digested with RNase-free DNase I (Qiagen, Valencia, CA) to remove DNA 
contamination. The concentration of the isolated RNA was determined by 
measuring the absorbance at 260 nm wave length with a spectrophotometer (Model 
DU 640, Beckman Coulter, Inc. Brea, CA). The ratio of A260/A280 was between 1.6 
and 1.8. Reverse transcription was carried out to synthesize cDNA in a 100 μl 
volume with 2 μg of total RNA, 10×RT buffer, 5.5 mM MgCl2, 2 mM dNTP mixture, 
0.125 μM oligo d(T), 0.125 μM random primer, 40 Units of RNase inhibitor, and 125 
Units of MultiScribe (Applied Biosystems, Foster City, CA) for 10 minutes at 25°C, 



































































Quantitative real-time RT-PCR 
Quantitative real-time RT-PCR was performed to determine the mRNA 
expression level of ALP and osteocalcin. The sequences of the primers were as 
follows: ALP (forward, 5‟-TCA GGG CAA TGA GGT CAC ATC-3‟; reverse, 5‟-CAC 
AAT GCC CAC GGA CTT C-3‟), osteocalcin (forward, 5‟-CGG CCC TGA GTC TGA 
CAA AG-3‟; reverse, 5‟-CTC GTC ACA AGC AGG GTC AA-3‟). Twenty-five 
microliters of reaction volume included 5 μl of cDNA, 0.5 μl of 10 μM of each primer 
and 12.5 μl of 2×SYBR green master mix (Applied Biosystems). Real-time PCR 
was performed with the following three-step protocol: step 1, 50°C for 2 minutes; 
step 2, 95°C for 10 minutes; step 3, 40 cycles of 95°C for 15 seconds and 62°C for 
1 minute using the 7500 real-time PCR System (Applied Biosystems, Foster City, 
CA). To confirm the amplification specificity, the PCR products were subjected to a 
dissociation curve analysis. The threshold cycles (Ct) of each reaction were 
normalized to those obtained for 18S mRNA using the –ΔΔCt method (Applied 
Bosystems). All PCR reactions were performed in triplicate. 
Alkaline phosphatase (ALP) assay 
 The C2C12 cells were plated at 200,000 cells/well in 6-well plates and 



































































replaced with DMEM containing 2 % FBS and the cells were treated with various 
concentrations of compound for 24 hours. On day 3, the medium was replaced with 
fresh DMEM containing 2% FBS and the cells were treated with 50 ng/ml of BMP-2 
for 72 hours. The cells were washed with phosphate-buffered saline (PBS) and 
lysed by addition of lysis buffer (10 mM Tris-HCl pH 8.0, 1 mM MgCl2 and 0.5 % 
Triton X-100). The cell lysates were centrifuged for 5 minutes at 13,000 x g. The 
supernatant was removed and the aliquots were assayed for ALP activity and 
protein amount. The ALP activity was measured in triplicate using an ALP assay kit 
(Sigma-Aldrich, St. Louis, MO) in microtiter plates. The protein amount was 
determined with Bio-Rad protein assay reagent (Bio-Rad, Hercules, CA) using 
bovine serum albumin (BSA) as a standard. The ALP activity (nmoles of 
p-nitrophenol per ml) was normalized to the protein amount (nmoles of 
p-nitrophenol per μg).  
Dual -luciferase reporter assay 
 The BMP-specific Smad1-driven 9×GCCG (a consensus binding 
sequence for Smad1) reporter plasmid was kindly provided by Dr. Miyazono (The 
Institute of Japanese Foundation for Cancer Research, Tokyo). The C2C12 cells 
were trypsinized and seeded in triplicate wells at 50,000 cells/well in 12-well plates 



































































and the renilla-luciferase control vector using SuperFect (Qiagen, Valencia, CA) for 
24 hrs. A total of 1 μg of plasmids was used for cotransfection in each well and the 
concentration of renilla-luciferase vector was 1/15 of the 9×GCCG-reporter plasmid. 
On day 3, medium was replaced with DMEM containing 2% FBS and the cells were 
treated with various concentrations of compound. On day 4, the cells were treated 
with BMP-2. On day 5, the luciferase activities were measured in 20 μl of cell-lysate 
using the dual-luciferase assay system (Promega, Madison, WI) with a luminometer 
(LumiCount; Packard Bioscience, Meriden, CT) following the manufacturer‟s 
instructions. The luciferase activity was expressed as relative units of luciferase 
(RUL; a ratio of firefly luciferase to renilla luciferase activity).  
Statistics and calculations 
 Results are presented as the mean of 3 determinations (n) with error bars 
representing the standard error of the mean (SEM). Experimental results that are 
visually represented are from consistent experiments where one representative 
experimental result is shown. Statistical significance (P<0.05) was calculated using 
a one-way analysis of variance (ANOVA) with Bonferroni Post Hoc test (equal 
variances assumed) or Dunnett‟s T3 Post Hoc test (equal variances not assumed) 
using Statistical Products for Social Sciences Version 16.0 (SPSS 16.0) for 



































































analysis. Statistical probability of P<0.05 was considered significant and is denoted 
as (*) in the figures. 
Determination of EC50  
The EC50 values were calculated by determining the concentration by 
which 50% of maximum activity was reached using the sigmoidal fit equation. The 
50% effective concentrations were determined with the standard curve analysis of 
SigmaPlot 8.02. The nonlinear regression equation is y = 
min+(max-min)/(1+(x/EC50)Hill Slope) where y is the observed responses; x is the dose 
concentration; max and min are approximated by the program automatically during 





































































Modeling and assignment of template structure to a Smurf1-interacting peptide and 
its target Smurf1-WW2 domain 
Smurf1 interaction with Smads is based on the presence of unique 
residues in WW2-domain of Smurf1 (Fig. 1) [11, 12]. These observations prompted 
us to embark on a drug design project based on the interacting domain of Smurf1. 
Since X-ray crystallographic or NMR-based structural data are lacking for 
the Smurf1 WW2 domain but homologous structures are available in the protein 
data bank, we used the homologous structures to discern a template model 
structure for the Smurf1 WW2 domain.  The WW-domains are mined from the 
SWISS-PROT and SP-TrEMBL protein databases.  We applied the „FindPattern‟ 
function in the Genetics Computer Group (GCG) software to search in databases 
for related „chordate‟ sequences for the Smurf1 WW2 domain. Modeling of a 
template structure for interacting domains is a critical pre-requisite for the 
subsequent identification of interacting residues. We accomplished this task for the 
Smad motif that interacts with Smurf1 [11].  We determined the model structure for 
the WW2-domain of Smurf1 and a Smurf1-interacting peptide motif as an example 



































































as well as SWISS_MODEL [15, 16] protein structure homology modeling servers 
(accessible via the ExPasy server at http:// swissmodel.expasy.org). We also used 
the HOMOLOGY module of the INSIGHT-II software of Accelrys Inc. to model the 
target peptide structure.  The HOMOLOGY module of INSIGHT-II helps in 
extracting the equivalent coordinates of the similar structure to build a model 
structure for the WW2-domain.  Once a backbone and side chains of the target 
peptide were built, we optimized the structure using the energy minimization 
protocol of the DISCOVER module of INSIGHT-II. In order to model the 
conformation of the target peptide, we used the related peptide fragment from the 
rat Enac Bp2 peptide complex (1I5H, PDB code). This complex has a WW domain 
bound to a peptide fragment that is similar to the N-terminal 10 residues of a 
10-residue model peptide that interacts with Smurf1, with three prolyl residues 
complexed with a homologous WW domain [11, 12].  The resultant model of the 
ten residue structure was considered as an example of Smurf1 target proteins.  
We compared these template models to obtain an acceptable model based on 
evaluation by the WHAT-CHECK and PRO-CHECK programs to correct the errors. 
These methods yielded optimum structure with stereochemically and energetically 
favored configuration. 



































































The LUDI de novo design method of Accelrys Inc. was used to identify the 
compounds that potentially block the Smurf1-WW2 domain. The important binding 
region within the WW2 domain was identified based on various studies on WW 
domains in the literature. The region around the residues: Tyr18, Val20, His22, Arg25, 
Thr27 and Phe29 was defined as the binding site with an appropriate radius of 9Å for 
LUDI docking covering the entire binding interface (Fig. 2). The LUDI search 
against the region gave about 400 molecules with a Ludi score greater than 300. In 
Fig. 2, we show a cluster of 10 top scoring molecules that occupy the binding region.  
The Ludi scoring approach was used to select 300 top scoring molecules. From 
these, we obtained 54 compounds from commercial sources for biochemical 
evaluation in living cells. Binding poses of 4 anonymous compounds are shown in 
Fig. 3. 
Optimization of a cell-based method to monitor BMP-2 induced responses 
 The mouse-derived C2C12 myoblasts served as an experimentally 
tractable model system for investigating the molecular basis of transdifferentiation 
towards the osteoblastic phenotype. We recently developed a sensitive and reliable 
cell-based assay utilizing a Smad1-specific luciferase reporter plasmid containing a 
multimerized –GCCG- motif (9 copies) to monitor transcriptional activity driven by 



































































reporter construct has been widely used to assay BMP activity in many cell types at 
a typical concentration of 50-100 ng/ml of BMP-2. To select a sub-optimal dose of 
BMP-2 for studying the potentiating effect of selected compounds, we performed 
the reporter assay with lower BMP-2 concentrations ranging from 0.25 to 25 ng/ml. 
The concentration range of BMP-2 required for activating the reporter assay was 
established (Fig. 4). The results from this experiment allowed us to select a 
sub-optimal dose (1.0 ug/ml) of BMP-2 to assess the potentiating effects of 
compounds in subsequent experiments.  
SVAK-12 potentiates BMP-2 induced Smad1-driven luciferase reporter activity  
 In an effort to identify a novel small drug-like molecule that could disrupt 
Smurf1-Smad1/5 interaction we used the computer simulation techniques of 
molecular docking for virtual screening. Compounds were ranked according to their 
relative binding energy, favorable shape complementarity, and potential to form 
hydrogen bonds within the modeled Smurf1 WW2 domain hydrophobic pocket [11, 
12]. For each docked compound, the best-scoring complexes were ranked, 
clustered, and re-ranked using calculations which included more accurate estimates 
of desolvation. Finally, a diversity selection, followed by visual inspection using 3D 
stereo-graphics of putative compounds, were employed as filters for discovery of 



































































compounds (54 compounds) was tested experimentally for their ability to potentiate 
BMP-2 activity in our luciferase reporter assay using C2C12 cells. Out of these 
candidate lead compounds, we selected SVAK-12 for the current studies as a 
promising synthetic compound (Fig. 5A and 5B). We focused on additional 
characterization of SVAK-12 activity because it showed relatively higher activity and 
its parent compound and the related chemical derivatives were pharmacologically 
more defined. The solvent dimethylsulfoxide (DMSO) controls showed only basal 
activity similar to no treatment controls. The DMSO solvent concentration of 0.01% 
(v/v) was not toxic to cells as determined by cell number, total protein amount and 
cell phenotype consistent with the literature (data not shown). At concentrations 
higher than 1.0 ug/ml, SVAK-12 caused lifting of cells from plates leading to 
decreased number of cells at the end of the experiment. 
Next, we determined the effectiveness of compound SVAK-12 on 
potentiation of BMP-2 activity over the concentration range from 0.125 to 1.0 ug/ml 
while keeping the BMP-2 concentration at 1 ng/ml in the luciferase reporter assay 
(Fig. 6). SVAK-12 caused a dose-dependent enhancement of the luciferase activity 
with an optimum enhancement of 3.8-fold (P<0.05) observed at a concentration of 
1.0 μg/ml when compared to BMP-2 alone. The concentration required for 



































































EC50 value was generated from fitted curves by solving for the x-intercept at the 
50% activity level of the Y-intercept as described in methods. The non-sigmoidal 
nature of the dose response curves of the compound is due to cell lifing induced at 
concentrations at or just above the maximal effective dose. After assay optimization, 
which included determining optimal BMP-2 concentration, plating density of cells, 
and compound incubation time, the promoter assay was shown to display the 
dynamic range and reproducibility required for a screening assay.  
BMP-2 induced alkaline phosphatase and osteocalcin mRNA levels are enhanced 
by the compound SVAK-12 
 We tested whether the compound, SVAK-12, that enhanced BMP-induced 
reporter activity would also exhibit potentiating activity on BMP-2-induced marker 
gene expression. We determined the effectiveness of compound SVAK-12 over the 
concentration range from 0.125 to 1.0 ug/ml while keeping the BMP-2 concentration 
constant at 20 ng/ml by determining alkaline phosphatase mRNA levels (Fig. 7). 
SVAK-12 caused a dose-dependent increase in the BMP-induced alkaline 
phosphatase mRNA level with the maximal 3.5-fold increase (P<0.05) compared to 
BMP-2 alone observed at a compound with a maximal concentration of 1.0 μg/ml. 



































































in the absence or the presence of DMSO (0.01%), respectively, when compared to 
the „no treatment‟ control (Fig. 7).  
We also tested whether the compound, SVAK-12, that enhanced 
BMP-induced reporter activity and ALP mRNA expression would exhibit potentiating 
activity by increasing BMP-2-induced osteocalcin gene expression. Such an 
observation would strengthen its biological role in promoting the osteoblastic 
phenotype. We determined the effectiveness of compound SVAK-12 over the 
concentration range from 0.125 to 1.0 ug/ml while keeping the BMP-2 concentration 
constant at 20 ng/ml, as shown in Fig. 8. SVAK-12 caused a dose-dependent 
increase in the BMP-induced osteocalcin mRNA level with a maximal 4.4-fold 
increase (P<0.05) compared to BMP-2 alone observed at a compound 
concentration of 1.0 μg/ml. BMP-2 alone induced a 9-fold or 7-fold increase in 
osteocalcin mRNA in the absence or the presence of DMSO (0.01%), respectively, 
when compared to „no treatment control‟(Fig. 8). An EC50 value in the range of 1.5 
to 5.3 uM was estimated for the expression of both alkaline phosphatase and 
osteocalcin mRNAs. 



































































We used SVAK-12 in the concentration range of 0.125 to 1.0 μg/ml while 
keeping the BMP-2 concentration constant at 50 ng/ml to evaluate its enhancement 
of the BMP-induced alkaline phosphatase activity. The ALP enzyme activity assay 
demonstrated that the compound dose-dependently enhanced the BMP-2 induced 
ALP activity. The peak activity of the maximal 4.8-fold increase (P<0.001) was 
observed at a compound concentration of 1.0 μg/ml when compared to BMP-2 
alone, further confirming the earlier observations (Fig. 9). An EC50 value of 3.7 uM 
was estimated for the activity of alkaline phosphatase. These results support our 
hypothesis that SVAK-12 is potentially a low-cost substitute for a recombinantly 




































































Increasing cellular responsiveness to BMP would be advantageous since 
bone formation in humans is requiring such high dose of rhBMPs. LMP-1 is an 
example of a naturally occurring protein that increases cellular response to BMPs. 
In this study, we sought to find a synthetic compound that blocks Smurf1 activity to 
enhance BMP responsiveness. We identified a unique compound, SVAK-12, that 
promotes the BMP-induced expression of phenotypic markers characteristic of a 
differentiated osteoblast. The reporter assays using BMP-specific Smad1-driven 
9×GCCG reporter plasmid, real-time RT-PCR for ALP and osteocalcin mRNA 
expression, and ALP enzyme activity assay all showed that the compound 
potentiated BMP-2 activity.  
Small synthetic chemical compounds (under 700 Daltons), can be more 
easily manufactured than recombinant proteins and are more amenable to 
production and scale-up for low-cost use. Small-molecule compounds with potential 
BMP-potentiating activity will provide a pharmacological approach to help further 
extend the therapeutic use of BMPs. Any identification of a low cost compound that 
potentiates a BMP-induced cellular response will broaden the use of BMP-2 for 
efficient bone regeneration application. Therefore, we extended the use of our 



































































active candidates among the synthetic compounds that were selected as “leads” 
after extensive chemo-informatic analyses of the Smurf1 WW2 domain and its 
interacting site in target proteins. We selected SVAK-12 as one such active “lead” 
candidates.  
To test the validity of the cell-based reporter assay further, we examined 
the potentiating activity of SVAK-12 on BMP-2-induced cellular responses. 
Real-time RT-PCR for ALP and osteocalcin mRNA expression and the ALP enzyme 
assay in C2C12 cells also demonstrated a dose-dependent activity of SVAK-12 in 
potentiating BMP-2 induced signaling. From these results we conclude that the 
activity of SVAK-12 is not dependent on any particular assay as similar 
BMP-potentiation effects were observed both in transfected and non-transfected 
cells.  
We applied lower concentrations of BMP-2 (0.125 - 5 ng/ml) than are 
typically used (50-100 ng/ml) so as to improve the sensitivity of our reporter assay 
in detecting enhancement of BMP-2 activity. We showed that the specificity of the 
assay was well maintained despite monitoring multiple cellular outputs at various 
time points. The compound SVAK-12 elevated the BMP-2-induced response 
significantly even at a dose of 0.1 μg/ml. The effective dose of compound remained 



































































markers in C2C12 cells that we chose to investigate are tightly controlled by the 
same BMP-signaling pathway. All these studies suggest that the compound, 
SVAK-12 or a potentially more efficacious derivative, may be useful in potentiating 
the BMP-2 responsiveness of cells. The combined use of such a compound with 
BMP-2 may reduce the high doses of BMP-2 protein currently required for its 
effective clinical use. The abundance and low cost of SVAK-12 makes it a highly 
desirable drug-candidate. Thus, SVAK-12 may be a useful pharmacological tool 
that induces BMP-mediated osteoblastic progression.  
In summary, we established the 9xGCCG reporter transfected C2C12 cells 
as a sensitive cell-based sensor of BMP-2 osteogenic effects. This system allowed 
us to monitor successfully the complex process of BMP-induced transdifferentiation 
of C2C12 cells towards the osteoblastic phenotype by determining various cellular 
markers at different time points in living cells. Also the identification and activity 
determination of SVAK-12 through novel chemo-informatics approach, virtual 
screenings and cell-based biochemical evaluations lay promising ground for further 
applications in bone biology. Future experiments will evaluate enhancement of 




































































Our results provide support for the idea that low molecular-weight 
compounds can inhibit protein–protein interactions that normally occur over 
relatively large surfaces. Also, our results raise the possibility of developing drugs 
that target Smurf1 via a novel mode of action and may inspire future rational 
development of compounds with the ability to modulate WW domain-dependent 
functions in other proteins. The rational development of compound SVAK-12 proves 
that small-molecule compounds can provide all the necessary requirements to 
block Smurf1 function. Currently, the compound selected in this study forms the 
basis of a medicinal chemistry effort to produce new chemical entities with 
optimized drug-like properties such as potency and bioavailability. Such compounds 
could have future applications in the treatment of disease by specifically modulating 
the WW domain-dependent interactions of a target protein. However, a major 
challenge is to further develop such compounds into high-affinity, specific and 
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Fig. 1. Optimized structure of the WW2 domain of Smurf1. The anti-parallel 
β-sheet structures are shown in ribbon form. 
Fig.2. Surface region of the Smurf1-WW2 domain is shown where the CAP small 
molecules are targeted. A group of consensus high scoring molecules are shown 
interacting with Smurf1-WW2 domain residues. The WW2 domain atoms are shown 
in stick form while the compounds are shown in ball and stick form. 
Fig.3. Binding poses are shown for four selected high scoring low-molecular weight 
molecules that were in the pool of 300 consensus high scoring molecules used for 
virtual testing. The WW2 domain atoms are shown in stick form while the 
compounds are shown in ball and stick form. 
Fig. 4. Determination of BMP-2 activity in a cell-based reporter assay. A 
dose-dependent induction of luciferase activity by BMP-2 is shown in C2C12 cells 
transfected with the BMP-specific and Smad1-driven 9×GCCG reporter plamid for 
24 hr. Luciferase activities were determined in triplicate. *Denotes statistical 
significance, determined as described in methods, between the indicated 



































































Fig. 5.  Determination of the efficacy of various selected compounds to enhance 
BMP-induced luciferase activity. Relative activities of a representative set of 
compounds in the luciferase reporter assay are shown. Compounds were tested at 
a concentration of 1.0 ug/ml while BMP-2 was used at 1.0 ng/ml. The 1.0 µg/ml 
compound concentration for screening was selected empirically. Data points were 
determined in triplicate. In “no compound” controls, cells were treated with DMSO 
(0.01%) alone.  
Fig. 6.  SVAK-12 potentiates BMP-2 responsiveness in the Smad1-driven reporter 
assay. A 3.8-fold enhancement of luciferase activity was observed at a SVAK-12 
concentration of 1.0 ug/ml when compared to BMP-2 alone (1 ng/ml). Data points 
were determined in triplicate.  Statistical significance from the BMP-2 control group 
was (P < 0.05) obtained as detailed in methods and is denoted by (*). 
Fig. 7. SVAK-12 enhances the BMP-induced increase of the ALP mRNA level in 
C2C12 cells. The compound dose-dependently enhanced the BMP-2 induced ALP 
mRNA level. The peak 3.5-fold enhancement of ALP mRNA level was observed at a 
SVAK-12 concentration of 1.0 μg/ml. Quantitation of the mRNA was based on 
triplicate determinations. *Denotes significant difference from BMP alone in the 



































































Statistical significance (P<0.05) among different groups was obtained as detailed in 
the Methods section. 
Fig. 8. SVAK-12 enhances the BMP-induced osteocalcin mRNA level in C2C12 
cells. The peak 4.4-fold enhancement of the osteocalcin mRNA level induced by 
BMP-2 was observed at a SVAK-12 compound concentration of 1.0 μg/ml. 
Quantitation of mRNA was based on triplicate determinations. *Denotes significant 
difference from BMP alone in the presence of equal amount of DMSO (0.01%) as in 
compound treatments. Statistical significance (P<0.05) among different groups was 
obtained as detailed in Methods section. 
Fig. 9.  Enhancement of BMP-2 induced ALP enzyme activity by SVAK-12. The 
compound dose-dependently enhanced the ALP activity induced by 50 ng/ml of 
BMP-2. The peak 4.8-fold enhancement of BMP-2-induced ALP activity was 
observed at a SVAK-12 compound concentration of 1.0 μg/ml. Data points were 
determined in triplicate. *Denotes significant difference from BMP alone control in 
the presence of equal amount of DMSO (0.01%) as in compound treatments. 
Statistical significance (P < 0.001) among different treatment groups was obtained 
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